141 related articles for article (PubMed ID: 33644844)
21. Clinicoetiological Study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Spectrum and the Correlation of SCORTEN with Prognosis.
Kanagarajan A; Murthy AB; Moni PK; Palanivel N
Indian J Dermatol; 2023; 68(1):25-33. PubMed ID: 37151260
[TBL] [Abstract][Full Text] [Related]
22. Comparison of performance of SCORTEN, ABCD-10 and Re-SCORTEN in a cohort of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis.
Hsieh TS; Chan TC; Cho YT; Chu CY
J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e514-e516. PubMed ID: 36377280
[No Abstract] [Full Text] [Related]
23. Epidemiology and costs of patients with toxic epidermal necrolysis: a 27-year retrospective study.
Oen IM; van der Vlies CH; Roeleveld YW; Dokter J; Hop MJ; van Baar ME
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2444-50. PubMed ID: 26416341
[TBL] [Abstract][Full Text] [Related]
24. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis.
Guégan S; Bastuji-Garin S; Poszepczynska-Guigné E; Roujeau JC; Revuz J
J Invest Dermatol; 2006 Feb; 126(2):272-6. PubMed ID: 16374461
[TBL] [Abstract][Full Text] [Related]
25. Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients.
Wambier CG; Hoekstra TA; Wambier SPF; Bueno Filho R; Vilar FC; Paschoal RS; Roselino AM; Frade MAC; Foss NT
An Bras Dermatol; 2019; 94(1):17-23. PubMed ID: 30726458
[TBL] [Abstract][Full Text] [Related]
26. Stevens-Johnson syndrome and toxic epidermal necrolysis: ear, nose, and throat description at acute stage and after remission.
Bequignon E; Duong TA; Sbidian E; Valeyrie-Allanore L; Ingen-Housz-Oro S; Chatelin V; Coste A; Wolkenstein P; Chosidow O; Papon JF
JAMA Dermatol; 2015 Mar; 151(3):302-7. PubMed ID: 25671761
[TBL] [Abstract][Full Text] [Related]
27. The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016-2018.
Sunaga Y; Kurosawa M; Ochiai H; Watanabe H; Sueki H; Azukizawa H; Asada H; Watanabe Y; Yamaguchi Y; Aihara M; Mizukawa Y; Ohyama M; Hama N; Abe R; Hashizume H; Nakajima S; Nomura T; Kabashima K; Tohyama M; Takahashi H; Mieno H; Ueta M; Sotozono C; Niihara H; Morita E; Kokaze A
J Dermatol Sci; 2020 Dec; 100(3):175-182. PubMed ID: 33046331
[TBL] [Abstract][Full Text] [Related]
28. Clinico- Therapeutic Study of Stevens Johnson Syndrome-Toxic Epidermal Necrolysis and Prognostic Significance of SCORTEN in Indian Patients.
Jangid NC; Choudhary AN; Shah BJ; Shah SR; Vyas HR; Mistry D
Indian J Dermatol; 2024; 69(1):24-31. PubMed ID: 38572027
[TBL] [Abstract][Full Text] [Related]
29. Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa: a 3-year prospective study.
Kannenberg SM; Jordaan HF; Koegelenberg CF; Von Groote-Bidlingmaier F; Visser WI
QJM; 2012 Sep; 105(9):839-46. PubMed ID: 22543685
[TBL] [Abstract][Full Text] [Related]
30. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases.
Chen J; Wang B; Zeng Y; Xu H
Eur J Dermatol; 2010; 20(6):743-7. PubMed ID: 20952352
[TBL] [Abstract][Full Text] [Related]
31. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.
Bastuji-Garin S; Fouchard N; Bertocchi M; Roujeau JC; Revuz J; Wolkenstein P
J Invest Dermatol; 2000 Aug; 115(2):149-53. PubMed ID: 10951229
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of histologic features of toxic epidermal necrolysis.
Valeyrie-Allanore L; Bastuji-Garin S; Guégan S; Ortonne N; Bagot M; Roujeau JC; Revuz JE; Wechsler J; Wolkenstein P
J Am Acad Dermatol; 2013 Feb; 68(2):e29-35. PubMed ID: 22088428
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
Yang Y; Xu J; Li F; Zhu X
Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
[TBL] [Abstract][Full Text] [Related]
34. Pediatric toxic epidermal necrolysis: using SCORTEN and predictive models to predict morbidity when a focus on mortality is not enough.
Beck A; Quirke KP; Gamelli RL; Mosier MJ
J Burn Care Res; 2015; 36(1):167-77. PubMed ID: 25559731
[TBL] [Abstract][Full Text] [Related]
35. Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center.
Lee HY; Fook-Chong S; Koh HY; Thirumoorthy T; Pang SM
J Am Acad Dermatol; 2017 Jan; 76(1):106-113. PubMed ID: 27717620
[TBL] [Abstract][Full Text] [Related]
36. Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience.
Nizamoglu M; Ward JA; Frew Q; Gerrish H; Martin N; Shaw A; Barnes D; Shelly O; Philp B; El-Muttardi N; Dziewulski P
Burns; 2018 May; 44(3):603-611. PubMed ID: 29029855
[TBL] [Abstract][Full Text] [Related]
37. Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome).
Monteiro D; Egipto P; Barbosa J; Horta R; Amarante J; Silva P; Silva A
Cutan Ocul Toxicol; 2017 Jun; 36(2):163-168. PubMed ID: 27487073
[TBL] [Abstract][Full Text] [Related]
38. Systemic therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN-based systematic review and meta-analysis.
Torres-Navarro I; Briz-Redón Á; Botella-Estrada R
J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):159-171. PubMed ID: 32946187
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the Factors Influencing Mortality in Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Study of 166 Patients.
Erduran F; Adışen E; Emre S; Hayran Y; Başkan EB; Yazıcı S; Bilgiç A; Alpsoy E; Günaydın SD; Elmas L; Akyol M; Güner R; Arıca DA; Aypek Y; Ergun T; Karavelioğlu D; Yazıcı AC; Aydoğan K; Bayramgürler D; Kıran R; Erdoğan HK; Acer E; Aktaş A
Dermatol Ther (Heidelb); 2024 Jun; 14(6):1547-1560. PubMed ID: 38758423
[TBL] [Abstract][Full Text] [Related]
40. [Ophthalmic manifestations after Lyell and Stevens-Johnson syndromes].
Mouafik SB; Hocar O; Akhdari N; Amal S; Belghmaidi S; Ennassiri W; Hajji I; Moutaouakil A
Ann Dermatol Venereol; 2015; 142(6-7):393-8. PubMed ID: 25896732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
